Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multi-Center, Randomized, Double-Blind, Placebo-Controlled Trial Comparing Standard of Care Adjuvant Temozolomide With or Without 5-Aminolevulinic Acid (5-ALA) With Concomitant Low Intensity Diffuse Ultrasound (LIDU) Sonodynamic Therapy (SDT) System In Patients With Newly Diagnosed Glioblastoma After Completion of Chemoradiotherapy

NCT07225621 is registered in ClinicalTrials.gov with Alpheus Medical, Inc. as lead sponsor.

NCT NCT07225621
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07225621 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Multi-Center, Randomized, Double-Blind, Placebo-Controlled Trial Comparing Standard of Care Adjuvant Temozolomide With or Without 5-Aminolevulinic Acid (5-ALA) With Concomitant Low Intensity Diffuse Ultrasound (LIDU) Sonodynamic Therapy (SDT) System In Patients With Newly Diagnosed Glioblastoma After Completion of Chemoradiotherapy
Lead sponsor
Alpheus Medical, Inc.
Phase
Phase 2
Overall status
Recruiting
Start date
January 28, 2026
Completion date
December 31, 2028
Enrollment
103 (estimated)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

gbm, glioblastoma